Leading market research patient recruitment firm Rare Patient Voice LLC announced another first-quarter 2022 round of promotions and changes to staff, following an initial round earlier in January.
If you are not happy with the results below please do another search
50 search results for:
Gilead Sciences Inc. said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of the company’s HIV treatments over the last two years, endangering patients.
While wealthier countries have come a long way to boosting their populations with an extra shot of COVID-19 vaccines to protect against Omicron, studies in Israel are evaluating whether a fourth dose of an mRNA vaccine offers additional protection. Although the data is still early, research suggests that it might not.
The U.S. Centers for Disease Control and Prevention (CDC) has said Americans should wear the most protective mask they can, but stopped short of recommending an N95 or similar face covering.
Stephen Hoelper, President, North America at Doceree, analyzes why life sciences brands need to move beyond vanity metrics for point-of-care campaigns.
Moderna is poised to commercialize the company’s COVID-19 and influenza combination vaccine by the fall of 2023, with some potential for the same drug to also be viable against respiratory syncytial virus (RSV).
There is no evidence at present that healthy children and adolescents need booster doses of COVID-19 vaccine, the World Health Organization’s chief scientist Soumya Swaminathan said on January 18.
The U.S. Food and Drug Administration extended the review period for bluebird bio’s Biologics License Applications (BLA) for two of the company’s lentiviral vector gene therapies.
The U.S. Food and Drug Administration issued a Complete Response Letter to Chicago’s Levo Therapeutics for the company’s New Drug Application for LV-101, which is being developed as a treatment for hyperphagia (excessive overeating), anxiousness and distress associated with Prader-Willi syndrome (PWS).
Ionis Pharmaceuticals announced that Roche, the company’s partner firm, is designing a new Phase II trial that would assess the effectiveness of tominersen in younger adult patients diagnosed with Huntington’s disease.